

9

1 475 151

PATENT SPECIFICATION

(11) 1 475 151




- (21) Application No. 26850/74 (22) Filed 18 June 1974
(31) Convention Application No. 9177/73
(32) Filed 22 June 1973
(31) Convention Application No. 9414/73
(32) Filed 28 June 1973
(31) Convention Application No. 9509/73
(32) Filed 29 June 1973
(31) Convention Application No. 9598/73
(32) Filed 2 July 1973 in
(33) Switzerland (CH)
(44) Complete Specification published 1 June 1977
(51) INT CL² C07D 211/44, 401/02, 409/02, 413/02 (C07D 401/02, 295/16) (C07D 409/02) (C07D 413/02, 211/44)
(52) Index at acceptance
C2C 1175 1341 1492 1532 1562 1582 1626 200 215 220 221
225 226 22Y 246 247 250 251 252 253 255 256 25Y
280 281 282 28X 29X 29Y 30Y 311 313 31Y 326 338
342 34Y 351 355 360 363 364 366 368 36Y 388 407
40Y 43X 509 50Y 574 584 594 623 624 625 628 62X
62Y 635 656 658 65X 662 665 668 66X 672 675 697
699 790 79Y BG KP KQ KR MB UJ UL
(72) Inventors ERWIN RISSI and ANTON EBNÖTHER

(54) PIPERIDIN-4-OL-DERIVATIVES

(71) We SANDOZ LTD., of 35 Lichtstrasse, 4002 Basle, Switzerland, a Swiss Body Corporate, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The present invention relates to new heterocyclic compounds.


In accordance with the invention there are provided new compounds of formula I,



wherein R₁ is phenethyl, phenethyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, 3-benzoylpropyl or 3-benzoylpropyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,

R₂ is an OR₃ group,

wherein R₃ is alkyl of 1 to 4 carbon atoms, alkenyl of 3 to 5 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or an



wherein independently each of R₆ and R₇ is hydrogen, alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms),

19

1,475,151

2

cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, phenylalkyl (of 1 to 4 carbon atoms) or lower phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or

wherein R_6 and R_7 together with the nitrogen atom to which they are bound, form a saturated heterocycle of 5 to 6 ring members, which may optionally contain as second hetero atom oxygen, sulphur or nitrogen substituted by alkyl of 1 to 4 carbon atoms,


R_3 is alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms), cycloalkyl of 4 to 6 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or when R_1 is phenethyl or phenethyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, alternatively lower alkenyl of 2 to 4 carbon atoms, and

R_4 is hydrogen or alkyl of 1 to 4 carbon atoms, or

R_3 and R_4 together with the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms.

Further, in accordance with the invention a compound of formula I may be obtained by a process comprising

a) reacting a compound of formula II,



II

wherein R_2 and R_4 are as defined above, and


R_3 is alkyl of 1 to 4 carbon atoms, cycloalkyl of 4 to 6 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or together with R_4 and the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms, with a compound of formula III,



III

wherein R_1 is as defined above, and


X is the acid radical of a reactive ester, to produce a compound of formula If,



If

wherein R_1 , R_2 , R_3 and R_4 are as defined above, or

b) producing a compound of formula Ia,




Ia

wherein R_5 and R_6 are as defined above,

R_2^1 is an OR₃ group,

wherein R₃ is as defined above, or an




wherein R₂¹ is alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms) cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, phenylalkyl (of 1 to 4 carbon atoms) or phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,

R₂¹ is hydrogen when R₂¹ and/or R₃ are phenyl or substituted phenyl, or

R₂¹ is alkyl of 1 to 4 carbon atoms or cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms phenylalkyl (of 1 to 4 carbon atoms) or phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, when R₂¹ is alkyl of 1 to 4 carbon atoms, cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms) or cycloalkyl of 4 to 6 carbon atoms, or R₂¹ is hydrogen and R₂¹ is phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or


R₂¹ and R₂¹ together with the nitrogen atom to which they are bound form a saturated heterocycle of 5 to 6 ring members, which may optionally contain as second hetero atom oxygen, sulphur, or nitrogen substituted by alkyl of 1 to 4 carbon atoms, and

R₃ is fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms by reacting a compound of formula IV,




IV

wherein R₈ is as defined above, with a compound of formula V,



V

wherein R₃, R₄ and R₂¹ are as defined above, or
c) producing a compound of formula Ib,




Ib

wherein R₂, R₂¹, R₄ and R₈ are as defined above,

12


1,475,151

by removing the protective group from a compound of formula VI,




VI

wherein R_2 , R_3 , R_4 and R_8 are as defined above, and
A is a carbonyl group protected by ketal formation, or
d) producing a compound of formula Ic,




Ic

wherein R_1 , R_3 and R_4 are as defined above,
by hydrolyzing the CN group to an NH_2 -CO group in a compound of formula VII,




VII

wherein R_1 , R_3 and R_4 are as defined above, or
e) producing a compound of formula Id,




Id

wherein R_1 , R_3 , R_4 , R_6 and R_7 are as defined above,
by reacting a compound of formula Ie,



Ie

wherein R_1 , R_3 and R_4 are as defined above, and
 R_5 is phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of
1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,
with a compound of formula VIII,



VIII

wherein R_6 and R_7 are as defined above.


13

5

1,475,151

5


In the compounds of formula I R_2 preferably signifies an



5 The substituents R_6 and R_7 preferably denote alkyl groups or cycloalkyl groups. When R_6 and R_7 are alkyl groups, these especially contain 1 or 2 carbon atoms. R_6 preferably signifies alkyl, especially methyl, and R_7 preferably signifies cycloalkyl, especially cyclohexyl. When R_6 is hydrogen, R_7 preferably signifies a phenyl group or a substituted phenyl group. When R_6 or R_7 contain phenyl groups substituted by alkyl or alkoxy groups, these especially signify methyl or methoxy. When R_6 and R_7 , together with the nitrogen atom form a heterocycle, this preferably signifies the morpholine or N-methylpiperazine or piperidine ring.

10 When R_2 in the compounds of formula I is an OR_3 group, R_3 preferably signifies alkyl or alkenyl. When R_3 is alkyl, this especially signifies methyl or ethyl. When R_3 is alkenyl, this especially signifies the allyl group. When R_3 signifies phenyl substituted by an alkyl or alkoxy group, these groups especially signify methyl or methoxy.

15 When R_2 in the compounds of formula I is an




20 R_1 preferably signifies a 3-benzoylpropyl group or a substituted 3-benzoylpropyl group. When R_2 is an OR_3 group, R_1 preferably signifies a phenethyl group or a substituted phenethyl group. When R_1 is a 3-benzoylpropyl group, this is preferably substituted by fluorine, which is preferably in the *p* position, or is unsubstituted. When the 3-benzoylpropyl group is substituted by alkyl or alkoxy, these groups especially signify the methyl or the methoxy group.

25 When R_1 is a phenethyl group, this is preferably substituted by chlorine, which is preferably in an *o* position, or is unsubstituted. When the phenethyl group is substituted by alkyl or alkoxy, these groups especially signify the methyl or the methoxy group.

30 The substituent R_3 preferably signifies alkyl or alkenyl, and the substituent R_4 preferably signifies hydrogen. When R_3 is alkyl, this especially signifies methyl or ethyl. When R_3 is alkenyl, this especially signifies vinyl. When R_3 is phenyl substituted by alkyl or alkoxy, these groups especially signify methyl or methoxy. When R_4 is alkyl, this especially signifies methyl.

35 The preferred compounds are those wherein R_1 is a 3-benzoylpropyl group or a 3-benzoylpropyl group substituted by fluorine preferably in the *p* position, R_2 is an



40 wherein R_6 is alkyl or cycloalkyl and R_7 is alkyl, or R_6 is hydrogen and R_7 is a phenyl group or a substituted phenyl group, or R_2 is an O-alkyl or an O-alkenyl group, and R_3 is alkyl and R_4 is hydrogen or alkyl. Specially suited compounds amongst these compounds containing a 3-benzoylpropyl group are those wherein R_2 is a preferably disubstituted amine radical, especially the dimethylamine or the N-cyclohexyl-N-methylamine radical.


45 Compounds which are also suitable are those wherein R_1 is a phenethyl group or a phenethyl group substituted by chlorine preferably in the *o* position, R_2 is an OR_3 group, wherein R_3 is alkyl, preferably methyl or ethyl, or alkenyl, or R_2 is an

(14)

6

1,475,151


6




wherein R_6 is alkyl or cycloalkyl and R_7 is alkyl, or R_6 is phenyl or substituted phenyl and R_7 is hydrogen, and R_8 is alkyl or alkenyl and R_9 is alkyl or hydrogen. Especially suited amongst these compounds containing a phenethyl group are those wherein R_2 is an O-alkyl or O-alkenyl, especially the methoxy, ethoxy or allyloxy group.

The reaction of a compound of formula II with a compound of formula III in accordance with process variant a) is preferably effected in an inert organic solvent, if desired with the addition of an acid-binding agent or in the presence of an excess of the compound of formula II used. Examples of inert solvents which may be used are, for example, aromatic hydrocarbons such as benzene, toluene or xylene, chlorinated hydrocarbons such as chloroform or carbon tetrachloride, or an alcohol (of 1 to 6 carbon atoms) such as ethanol, or DMF or DMA. Examples of acid-binding agents which may be used are alkali metal carbonates such as potassium carbonate or sodium carbonate, or tertiary amines such as triethylamine or pyridine. It is preferred to use compounds of formula III wherein X is chlorine, bromine, iodine or the radical of an organic sulphonic acid, for example an alkylsulphonyloxy or an arylsulphonyloxy radical. The reaction is preferably effected at a temperature between room temperature and approximately 100°C.

The addition of an ester or an amide of formula V on a 4-piperidone derivative of formula IV in accordance with process variant b) may, for example, be effected in the presence of a strong basic condensation agent. Examples of inert anhydrous solvents which may be used are saturated hydrocarbons such as hexane, ethers such as diethyl ether or tetrahydrofuran, or aromatic hydrocarbons such as benzene or toluene. Especially suited is, for example, a mixture of hexane/tetrahydrofuran. When the $\text{CO}-R_1^1$ group in the compounds of formula V is an ester group or a tertiary amide group, suitable basic condensation agents are alkali metal amides such as lithium or sodium amide, it being preferred to use organic lithium amides, especially diisopropyl lithium amide, cyclohexylmethyl lithium amide or cyclohexylisopropyl lithium amide, and the reaction may be effected at low temperatures, preferably at a temperature between -75 and -20°C. If desired, a catalytic amount of an organic peroxide or of dimethyl sulphoxide may be added in order to accelerate the reaction when using lithium or sodium amide. When the $\text{CO}-R_1^1$ group is a secondary phenylamide group or a substituted secondary phenylamide group, the addition may be effected in the presence of a very strong basic condensation agent capable of forming a dianion of formula Va,



wherein R_3 , R_4 and R_5 are as defined above, from an amide of formula Vb,



wherein R_3 , R_4 and R_5 are as defined above.

Examples of suitable compounds therefor are lower alkyl alkali metal compounds, preferably lower alkyl lithium compounds, especially n-butyl lithium or methyl lithium, or also phenyl lithium or organic Grignard compounds, e.g. alkyl magnesium halides. The reaction temperature may be between 0 and 50°C.

The removal of the protective groups from ketals of formula VI in accordance with process variant c) may be effected in known manner. Examples of suitable protective groups of the carbonyl function are optionally mixed ketals of lower 1- or 2-valent alcohols. It is preferred to use cyclic ketals with 5 or 6 ring members,

especially dioxolane. The ketal splitting may be effected on crude ketals of formula VI, for example by hydrolysis in an acid medium, e.g. with a dilute mineral acid, e.g. with approximately 2 N hydrochloric acid, preferably at a temperature between 0 and 25°C. When the CO—R₂ group in the compounds of formula VI is an ester group, the reaction conditions for the ketal splitting must be so mild that a simultaneous ester splitting is avoided.

The production of compounds of formula Ic in accordance with process variant d) may be effected in accordance with the usual methods for the hydrolysis of cyanides. The compounds of formula VII may, for example, be reacted with water, optionally with the addition of a further inert organic solvent, preferably miscible with water, e.g. an alcohol (of 1 to 6 carbon atoms), acetone or dioxane, preferably in the presence of a basic catalyst. The hydrolysis is preferably effected in an alkaline medium, e.g. in the presence of dilute alkali metal hydroxide solutions, e.g. dilute caustic soda solution. In accordance with a preferred method of the process the compounds of formula VII are converted into amides of formula Ic in the presence of an alcohol of 1 to 6 carbon atoms and a dilute, e.g. a 1 N to 5 N caustic soda solution, with a hydrogen peroxide solution at a slightly elevated temperature, e.g. at a temperature between 20 and 50°C. Any N-oxides which may result as by-products may be reduced to compounds of formula Ic by subsequent treatment of the crude reaction product with sodium disulphite solution in an aqueous medium at a low temperature, preferably at a temperature between 0 and 20°C.


The formation of amides of formula Id from the phenyl esters of formula Ie may be effected in known manner by reacting the esters of formula Ie with preferably an excess of an amine of formula VIII, e.g. at an elevated temperature, preferably at a temperature between 50 and 150°C. When amines having a low boiling point are used, the reaction may preferably be effected in an autoclave under pressure. If desired, an inert organic solvent may be added to the reaction mixture. Examples of suitable solvents are aromatic hydrocarbons such as benzene or xylene, cyclic ethers such as dioxane or tetrahydrofuran, dimethyl formamide or dimethyl acetamide.

The compounds of formula I may be isolated from the reaction mixture and purified in known manner. Free base forms of the compounds may be converted into acid addition salt forms in known manner, and *vice versa*.

Suitable inorganic acids for salt formation include hydrochloric acid and hydrobromic acid and suitable organic acids include fumaric acid, maleic acid and naphthalene 1,5-disulphonic acid.

The starting materials may be obtained as follows:

- a') Compounds of formula II may, for example, be obtained by debenzylating in known manner a compound of formula IX,




IX

wherein R₂, R₃ and R₄ are as defined above.

The removal of the benzyl group may, for example, be effected by catalytic hydrogenation, whereby any double bonds which may be present in the radicals R₃ or R₄ are likewise hydrogenated.

- b') Compounds of formula II wherein R₂ is an O-alkenyl group, are preferably obtained by an interchange of ester radicals in a corresponding alkyl ester (R₂ = an O-alkyl group) with an alkenol in known manner.
- c') Amides of formula IIa,



IIa

16

1,475,151

8

8

wherein R_3^I , R_4 , R_5 and R_7 are as defined above, may, for example, also be obtained by reacting a corresponding phenyl ester of formula II ($R_2 = O\text{-phenyl}$) with a compound of formula VIII, for example under the reaction conditions described in process variant e).

5 d') Compounds of formula VI may, for example, be obtained by reacting a compound of formula II with a compound of formula X,




wherein R_5 , A and X are as defined above.

The reaction may, for example, be effected under the reaction conditions described in process variant a).


10

10

e') Compounds of formula VIIa,



wherein R_1 , R_3^I and R_4 are as defined above, may, for example, be obtained by reacting a compound of formula XI,



15


15

wherein R_3^I and R_4 are as defined above, with a compound of formula III or a compound of formula X, for example under the reaction conditions described in process variant a), and any ketal protective groups which may be present are subsequently removed.

20

20

f') Compounds of formula VIIa,



wherein R_3 , R_4 and R_5 are as defined above, may, for example, be obtained by reacting a compound of formula IV with a compound of formula XII,




25

25

wherein R_3 and R_4 are as defined above, for example under the reaction conditions described in process variant b).


17

g') Compounds of formula IXa,




wherein R_1 , R_3 and R_4 are as defined above, may, for example, be obtained by reacting N-benzylpiperidone with a compound of formula V, for example under the reaction conditions described in process variant b).

h') Compounds of formula IXb,



wherein R_3 , R_4 , R_6 and R_7 are as defined above, may, for example, also be obtained by reacting a corresponding phenyl ester of formula IXa ($R_1 = O$ -phenyl) with a compound of formula VIII, for example under the reaction conditions described in process variant e).

i') Compounds of formula IXb wherein R_6 and R_7 are hydrogen, may, for example, also be obtained by hydrolysis of a nitrile of formula XIII,



wherein R_3 and R_4 are as defined above, for example under the reaction conditions described in process variant d).

j') Compounds of formula XI may, for example, be obtained by reacting N-benzyl-4-piperidone with a compound of formula XII, for example under the reaction conditions described in process variant b), and the resulting compounds of formula XIII may subsequently be debenzylated, for example by catalytic hydrogenation in a manner analogous to that described in process variant a').

Insofar as the production of the starting materials is not described, these are known or may be produced in accordance with known processes, or in a manner analogous to the processes described herein or to known processes.

In the following non-limitative Examples all temperatures are indicated in degrees Centigrade.

18

10

1,475,151

10

EXAMPLE 1.

2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]propionic acid ethyl ester [process variant a)]

A solution of 8.6 g of 4-chlorobutyrophenone in 30 cc of N,N-dimethyl formamide is added dropwise at 60°, with stirring, to a solution of 18.9 g of crude 2-(4-hydroxy-4-piperidyl)propionic acid ethyl ester in 250 cc of N,N-dimethyl formamide. The reaction mixture is allowed to react at 60° for 7 1/2 hours, the solvent is removed by evaporation at reduced pressure and the resulting residue is taken up in chloroform. The chloroform solution is repeatedly extracted with water, dried over magnesium sulphate and evaporated to dryness. The resulting residue is dissolved in ethanol, hydrochloric acid in ethanol is added and subsequently ether is added until the reaction solution is turbid, and the resulting crude crystalline product is purified by repeated crystallization from ethanol/ether. The hydrochloride form of the title compound, having a M.P. of 130—132°, is obtained.

The 2-(4-hydroxy-4-piperidyl)propionic acid ethyl ester, used as starting material, is produced as follows:

a) A solution of 23 cc of propionic acid ethyl ester in 100 cc of anhydrous tetrahydrofuran is added dropwise at -75° to a solution of N,N-diisopropyl lithium amide (produced from 56.7 cc of N,N-diisopropylamine in 300 cc of anhydrous tetrahydrofuran and 160 cc of a 20% n-butyl-lithium solution in hexane at a temperature of -75°). The reaction mixture is stirred at the same temperature for one hour and a solution of 37.8 g of 1-benzyl-4-piperidone in 100 cc of anhydrous tetrahydrofuran is subsequently added dropwise at -75°. After allowing to react at the same temperature for one hour, the reaction mixture is allowed to warm to about -10° and is decomposed with 200 cc of a 20% potassium carbonate solution. Extraction is repeatedly effected with ether, the extracts are dried over magnesium sulphate and evaporated to dryness. The resulting 2-(1-benzyl-4-hydroxy-4-piperidyl)propionic acid ethyl ester is used as crude product for the next reaction.

b) A solution of 57.1 g of 2-(1-benzyl-4-hydroxy-4-piperidyl)propionic acid ethyl ester in 580 cc of glacial acetic acid is hydrogenated in the presence of 5.7 g of a palladium catalyst (10% on charcoal) at a temperature of 70° and a pressure of 21 atmospheres in a 1-litre autoclave. After the calculated amount of hydrogen has been taken up, the reaction mixture is filtered and evaporated to dryness. The residue is dissolved in 600 cc of chloroform and a paste of 216 g of potassium carbonate and 100 cc of water is added to this solution while cooling with ice and stirring. The chloroform solution is decanted, the mash remaining in the reaction vessel is washed with chloroform and the chloroform phases which have been dried over magnesium sulphate are concentrated by evaporation. The resulting 2-(4-hydroxy-4-piperidyl)propionic acid ethyl ester is used as crude product for the next reaction.

EXAMPLE 2.

2-[1-(4-p-fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]propionic acid ethyl ester

[process variant c)]

20.5 g of crude 2-[1-[4-(1,2-ethylenedioxy)-4-(p-fluorophenyl)-butyl]-4-hydroxy-4-piperidyl]propionic acid ethyl ester are taken up in 750 cc of chloroform, 300 cc of 2 normal hydrochloric acid are added to the solution and this is stirred at room temperature for 11 hours. The chloroform phase is separated, dried over magnesium sulphate and concentrated by evaporation. The free base is recrystallized from ethanol with the addition of ether and is then converted into the hydrochloride. This has a M.P. of 183—185°.

The starting material may be obtained as follows:

a) 10.2 g of sodium carbonate are added to a solution of 9.7 g of crude 2-(4-hydroxy-4-piperidyl)propionic acid ethyl ester in 100 cc of dimethyl formamide and the mixture is heated to 100°. 13.0 g of 2-(3-chloropropyl)-2-(p-fluorophenyl)-1,3-dioxolane in 25 cc of dimethyl formamide are then added dropwise within 15 minutes and stirring is subsequently effected at 100° for 5 hours. The dimethyl formamide is removed by evaporation at reduced pressure, the resulting compound is used for the next reaction without purification.

(19)

The following compounds may also be obtained in a manner analogous to Example 1 or 2, by reaction of the corresponding (4-hydroxy-4-piperidyl)carboxylic acid esters, produced in a manner analogous to Example 1 a) and b), with the corresponding 4-chlorobutyrophenone derivatives or by splitting the corresponding 2-phenyl-2-[3-(4-hydroxypiperidyl)propyl]-1,3-dioxolane derivatives produced in a manner analogous to Example 2 a):

Compound	Observations, physical constants
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-butyric acid ethyl ester	M.P. of the hydrochloride form: 152—154° (from ethanol)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-cyclohexyl-acetic acid ethyl ester	M.P. of the hydrobromide form: 142—144° (from ethanol/ether)
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-propionic acid ethyl ester	M.P. of the hydrochloride form: 183—185° (from acetone)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-isobutyric acid ethyl ester	M.P. of the neutral naphthalene-1,5-disulphone form: 238—239.5° (from ethanol or methanol)
1-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-1-cyclopentane-carboxylic acid ethyl ester	M.P. of the hydrochloride form: 154—156° (from acetone)
2-cyclopentyl-2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]acetic acid ethyl ester	M.P. of the hydrobromide form: 136.5—138° (from ethanol/ether)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-3-cyclopentyl-propionic acid ethyl ester	M.P. of the hydrogen fumarate form: 134—136° (from acetone)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-3-cyclohexyl-propionic acid ethyl ester	M.P. of the hydrobromide form: 150—151.5° (from ethanol/ether)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-propionic acid tert.butyl ester	M.P. of the hydrogen maleate form: 135—136°
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-isobutyric acid ethyl ester	M.P. of the maleate form: 99—100° (from acetone/ether)
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-isobutyric acid methyl ester	M.P. of the maleate form: 80—82° (from acetone/ether)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-propionic acid <i>o</i> -tolyl ester	
2-[4-hydroxy-1-(4-oxo-4- <i>m</i> -tolylbutyl)-4-piperidyl]-isobutyric acid ethyl ester	
2-[4-hydroxy-1-(4- <i>p</i> -methoxyphenyl-4-oxobutyl)-4-piperidyl]propionic acid ethyl ester	
2-[1-(4- <i>p</i> -chlorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-2-phenylacetic acid ethyl ester	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-isobutyric acid allyl ester	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]propionic acid phenyl ester	

Compound	Observations, physical constants
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-propionic acid <i>m</i> -methoxyphenyl ester	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-butyric acid <i>p</i> -chlorophenyl ester	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2- <i>p</i> -chlorophenyl-acetic acid ethyl ester	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-phenylacetic acid ethyl ester	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-2- <i>m</i> -tolyl-acetic acid ethyl ester	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-2- <i>p</i> -methoxyphenylacetic acid ethyl ester	

EXAMPLE 3:

2-(4-hydroxy-4-piperidyl-1-phenethyl-4-piperidyl)propionic acid ethyl ester
[process variant a)]

- 5 A solution of 12.0 g of phenethyl bromide in 50 cc of dimethyl formamide is added dropwise at a temperature of 60°, with stirring, to a suspension of 18.9 g of crude 2-(4-hydroxy-4-piperidyl)propionic acid ethyl ester and 11.5 g of potassium carbonate in 150 cc of dimethyl formamide. The reaction mixture is stirred at 60° for a further 1½ hours, is then poured in a 10% potassium carbonate solution containing ice and extraction is effected with ether. The title compound, obtained after drying the ether extracts over magnesium sulphate and concentrating by evaporation, is dissolved in acetone, the calculated amount of maleic acid is added, and the resulting crude hydrogen maleate is repeatedly recrystallized from acetone. The hydrogen maleate form of the title compound has a M.P. of 138—139°.
- 10
- 15

The following compounds may be obtained in a manner analogous to Example 3, by reaction of the corresponding (4-hydroxy-4-piperidyl)carboxylic acid esters produced in a manner analogous to Example 1 a) and b), with the corresponding β -halogen-phenethyl derivatives:

Compound	Observations, physical constants
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid isopropyl ester	M.P. of the hydrogen fumarate form: 138—139° (from acetone)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid tert. butyl ester	M.P. of the hydrogen fumarate form: 151—152° (from ethanol/ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2-phenylacetic acid ethyl ester	M.P. 93—96° (from ether/petroleum ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2- <i>p</i> -chlorophenyl-acetic acid ethyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid phenyl ester	M.P. (HCl salt) 177—178° (from acetone)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid methyl ester	M.P. (hydrogen maleate salt) 122—123° (from acetone/ether)

Compound	Observations, physical constants
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-isobutyric acid ethyl ester	M.P. of the hydrogen maleate form: 147—148° (from acetone/ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid allyl ester	M.P. of the hydrogen maleate form: 96—99° (from acetone)
2-(4-hydroxy-1- <i>o</i> -methoxyphenethyl-4-piperidyl)-propionic acid ethyl ester	
2-(4-hydroxy-1- <i>m</i> -methylphenethyl-4-piperidyl)-propionic acid ethyl ester	
2-(1- <i>p</i> -fluorophenethyl-4-hydroxy-4-piperidyl)-propionic acid ethyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2- <i>p</i> -fluorophenyl-acetic acid ethyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2- <i>m</i> -methoxyphenyl-acetic acid ethyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2- <i>p</i> -tolyl-acetic acid ethyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid <i>p</i> -chlorophenyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid <i>o</i> -tolyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionic acid <i>p</i> -fluorophenyl ester	
1-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-1-cyclohexane-carboxylic acid ethyl ester	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-isobutyric acid allyl ester	M.P. (hydrogen maleate) 100—102° (from acetone)

EXAMPLE 4.

2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N,N-dimethyl propionamide [process variant a)]

- 5 A solution of 18.1 g of 4-chlorobutyrophenone in 30 cc of N,N-dimethyl formamide is added dropwise at 60°, with stirring, to a solution of 39.6 g of 2-(4-hydroxy-4-piperidyl)propionic acid N,N-dimethylamide in 150 cc of N,N-dimethyl formamide. The mixture is allowed to react at 60° for 6 hours, the solvent is removed by evaporation at reduced pressure and the resulting residue is taken up in chloroform. The chloroform solution is repeatedly extracted with water, is dried over magnesium sulphate and evaporated to dryness. The resulting residue is dissolved in ethanol, the calculated amount of fumaric acid is added to the solution and ether is subsequently added until the solution becomes turbid. Purification is effected by recrystallizing the crude hydrogen fumarate repeatedly from ethanol/ether. The hydrogen fumarate form of the title compound, having a M.P. of 155—157°, is obtained. 5
- 10
- 15

The starting material is obtained as follows:

- a) A solution of 20.2 g of propionic acid N,N-dimethylamide in 75 cc of anhydrous tetrahydrofuran is added dropwise at -75° to a solution of N,N-diisopropyl-lithium amide (produced from 35 g of diisopropylamine in 200 cc of anhydrous 20

22
14

1,475,151

14

tetrahydrofuran and 100 cc of a 20% n-butyllithium solution in hexane at a temperature of -75° . After stirring at the same temperature for one hour, a solution of 37.8 g of 1-benzyl-4-piperidone in 150 cc of tetrahydrofuran is added within 20 minutes and the mixture is allowed to react for 2 hours at about -70° . The reaction temperature is then allowed to rise to about -10° and the reaction mixture is decomposed with 300 cc of a 20% potassium carbonate solution. After extracting repeatedly with ether, the crude product is isolated by drying the extracts over magnesium sulphate and concentrating by evaporation. The resulting crude 2-(1-benzyl-4-hydroxy-4-piperidyl)propionic acid N,N-dimethylamide is used for the next reaction without purification.

- b) 57.7 g of 2-(1-benzyl-4-hydroxy-4-piperidyl)-propionic acid N,N-dimethylamide in 1000 cc of glacial acetic acid are hydrogenated at 70° and a pressure of 21 atmospheres, in the presence of 5.8 g of a palladium catalyst (10% on charcoal). After the take up of the calculated amount of hydrogen, the reaction mixture is filtered and evaporated to dryness. The residue is dissolved in 600 cc of chloroform and a paste of 216 g of potassium carbonate and 100 cc of water is added to this solution while cooling with ice and stirring. The chloroform solution is decanted, the mash remaining in the reaction vessel is washed with chloroform and the chloroform phases which have been dried over magnesium sulphate are concentrated by evaporation. The resulting 2-(4-hydroxy-4-piperidyl)propionic acid N,N-dimethylamide is used as crude product for the next reaction.

EXAMPLE 5.

2-[1-(4-p-fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N-phenylpropionamide [process variant c)]

21.5 g of crude 2-[1-[4-(2,2-ethylenedioxy)-4-p-fluorophenylbutyl]-4-hydroxy-4-piperidyl]-N-phenylpropionamide are taken up in 750 cc of chloroform and stirring is effected at 25° for 10 hours with the addition of 400 cc of 2 N hydrochloric acid. The organic phase is separated and concentrated by evaporation at reduced pressure and the residue is taken up in 2 N hydrochloric acid. The acid aqueous solution is extracted twice with ether, is rendered alkaline with a 2 N caustic soda solution while cooling with ice and the resulting title compound is extracted with ether. The resulting crude product is dissolved in acetone, an equivalent amount of maleic acid is added, and after the addition of ether crystallizes as maleate. M.P. of the maleate form of the title compound: $111-113^{\circ}$.

The starting material may be obtained as follows:

- a) 48 cc of n-butyl-lithium are added dropwise at 0° , in an atmosphere of nitrogen and with stirring, to a solution of 9 g of N-phenylpropionamide in 90 cc of anhydrous tetrahydrofuran. The mixture is stirred for a further 2 1/2 hours at $45-48^{\circ}$ and a solution of 7.9 g of N-benzyl-4-piperidone in 25 cc of anhydrous tetrahydrofuran is added dropwise within 50 minutes. The heating (oil bath) is removed and the reaction mixture is stirred for a further hour while cooling slowly. The reaction solution is then decomposed with 10 cc of a 20% potassium carbonate solution while stirring and cooling with ice, dilution is effected with ether and the organic phase is decanted, dried over magnesium sulphate and concentrated by evaporation at reduced pressure. The resulting crude 2-(1-benzyl-4-hydroxy-4-piperidyl)-N-phenylpropionamide is purified over silica gel (eluant: chloroform containing 3% of methanol) and after concentrating the solution in ethanol, an equivalent amount of fumaric acid is added thereto, whereby the product crystallizes as fumarate. M.P. $228-239^{\circ}$.
- b) A solution of 16.0 g of 2-(1-benzyl-4-hydroxy-4-piperidyl)-N-phenylpropionamide in 160 cc of glacial acetic acid is hydrogenated at a temperature of 50° and a pressure of 31 atmospheres for 15 hours in the presence of 1.6 g of a palladium catalyst (10% on charcoal). The reaction mixture is worked up in a manner analogous to that described in Example 4 b) and the resulting 2-(4-hydroxy-4-piperidyl)-N-phenylpropionamide is used as crude product for the next reaction.
- c) 11.0 g of potassium carbonate are added to a solution of 11.0 g of crude 2-(4-hydroxy-4-piperidyl)-N-phenylpropionamide in 150 cc of dimethyl acetamide and the mixture is heated to 100° while stirring. A solution of 13.1 g of 2-(3-chloropropyl)-2-(p-fluorophenyl)-1,3-dioxolane in 20 cc of dimethyl acetamide is subsequently added dropwise while stirring vigorously and the temperature is

23

kept at 100° for 4 hours. The solution is subsequently cooled and the potassium carbonate is filtered off and the filtrate concentrated by evaporation at reduced pressure. The resulting compound is used for the next reaction without purification.

5 The following compounds may be obtained in a manner analogous to that described in Example 4 or 5, by reacting the corresponding (4-hydroxy-4-piperidyl)-carboxylic acid amides, produced in a manner analogous to Example 4 a) and b), with the corresponding 4-chlorobutyrophenone derivatives, or by splitting the corresponding 2-phenyl-2-[3-(4-hydroxypiperidyl)propyl]-1,3-dioxolane derivatives produced in a manner analogous to Example 5 a) to c):

Compound	Observations, physical constants
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N-cyclohexyl-N-methyl propionamide	M.P. of the hydrobromide form: 190—191.5° (from isopropanol)
2-[1-(4-fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N,N-dimethyl propionamide	M.P. of the hydrochloride form: 200—202° (from ethanol/ether)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N-methyl-N-phenyl propionamide	M.P. of the hydrogen fumarate form: 203—204° (from ethanol)
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N-methyl-N-phenyl propionamide	M.P. of the hydrogen maleate form: 146—148°
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N,N-dimethylisobutyric acid amide	M.P. of the hydrochloride form: 215—216° (from ethanol)
1-[2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-methylpropionyl]pyrrolidine	M.P. of the hydrochloride form: 192—194° (from acetone)
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N-isopropyl-N-methyl isobutyric acid amide	
N-cyclohexyl-2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N-isopropyl-propionamide	
2-[4-hydroxy-1-(4-oxo-4- <i>p</i> -tolylbutyl)-4-piperidyl]-N- <i>p</i> -chlorophenyl-N-methyl propionamide	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N-cyclohexyl-N-methyl-2-phenylacetamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N- <i>p</i> -fluorophenyl-N-methyl propionamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N- <i>m</i> -methoxyphenyl propionamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-2- <i>p</i> -chlorophenyl-N- <i>o</i> -tolyl-acetamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-propionamide	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-propionamide	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-phenylacetamide	
2-cyclohexyl-2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]acetamide	



1,475,151

16

Compound	Observations, physical constants
N-cyclohexyl-2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-N-isopropyl-isobutyric acid amide	
N-cyclohexyl-2-[4-hydroxy-1-(4- <i>p</i> -chlorophenyl-4-oxobutyl)-4-piperidyl]-N-methyl propionamide	
1-[2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-methylpropionyl]-4-methylpiperazine	
1-[2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-methylpropionyl]morpholine	
1-[2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-methylpropionyl]thiomorpholine	
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-cyclohexyl-N,N-dimethylacetamide	
2-[1-(4- <i>p</i> -methoxyphenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N-benzyl-N-methyl propionamide	
1-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-1-cyclohexanecarboxylic acid N,N-dimethylamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N-isopropyl-N-methyl-2- <i>p</i> -methoxyphenylacetamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-2- <i>p</i> -fluorophenyl-N,N-dimethyl acetamide	
2-[1-(4- <i>p</i> -fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]-N,N-dimethyl-2- <i>m</i> -tolyl-acetamide	

EXAMPLE 6.

5 The following compounds may also be obtained in a manner analogous to that described in Example 3, by reacting the corresponding (4-hydroxy-4-piperidyl)-carboxylic acid amides, produced in a manner analogous to Example 4 a) and b), with the corresponding β -halogen-phenethyl derivatives: 5

Compound	Observations, physical constants
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-butylpropionamide	M.P. (hydrogen maleate) 132—133° (from acetone/ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N- <i>m</i> -tolyl-N-methyl propionamide	
2-(1- <i>m</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-isopropyl propionamide	
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionyl]-thiomorpholine	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dibutyl-2-cyclohexyl-acetamide	M.P. of the hydrogen fumarate form: 159.5—160.5° (from ethanol)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dibutyl-propionamide	M.P. of the hydrogen maleate form: 140—141.5° (from acetone/ether)

Compound	Observations, physical constants
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methylpropionic acid amide	M.P. of the hydrogen maleate form: 121—123° (from acetone)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dimethylpropionamide	M.P. of the hydrogen fumarate form: 156—158° (from ethanol/ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dimethyl-2-cyclohexyl-acetamide	M.P. of the hydrobromide form: 203.5—205° (from ethanol)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-methyl-N-phenylpropionamide	M.P. of the hydrogen maleate form: 170.5—171.5° (from ethanol)
2-(1- <i>o</i> -fluorophenyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methylpropionamide	
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionyl]-4-methylpiperazine	M.P. of the dihydrochloride form: 283—284° (from ethanol)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-isobutyric acid N,N-dimethylamide	M.P. (hydrogen fumarate) 196—197°C
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2-methylpropionyl]-piperidine	M.P. 132—133° (from acetone)
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionyl]-morpholine	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-methyl-N-phenyl-2- <i>m</i> -tolyl-acetamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N- <i>p</i> -fluorophenyl-N-methylpropionamide	
N-benzyl-2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-3-cyclohexyl-N-methylpropionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2- <i>p</i> -chlorophenyl-N,N-dimethylacetamide	
1-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methyl-1-cyclohexane-carboxylic acid amide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-2- <i>p</i> -methoxyphenyl-N-methylacetamide	M.P. (hydrochloride) 238—239° (from acetone/ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methyl isobutyric acid amide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-isopropyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-isopropyl-N-methyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-2- <i>p</i> -fluorophenyl-N-methylacetamide	
N-cyclohexyl-2-(1- <i>m</i> -methylphenethyl-4-hydroxy-4-piperidyl)-N-methyl propionamide	

gl

18

1,475,151

18

Compound	Observations, physical constants
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)- <i>N</i> -cyclohexyl-2-phenyl- <i>N</i> -methylacetamide	
2-(4-hydroxy-1- <i>o</i> -methoxyphenethyl-4-piperidyl)- <i>N</i> -cyclohexyl- <i>N</i> -methyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)- <i>N</i> -phenyl isobutyric acid amide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)- <i>N</i> - <i>p</i> -chlorophenyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)- <i>N</i> - <i>p</i> -tolyl-propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)- <i>N</i> - <i>m</i> -methoxyphenyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)- <i>N</i> -phenyl propionamide	M.P. of the hydrogen fumarate form: 159—161° (from ethanol)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionamide	M.P. of the hydrogen maleate form: 219—221° (from acetone)
2-cyclohexyl-2-(4-hydroxy-1- <i>m</i> -methylphenethyl-4-piperidyl)- <i>p</i> -fluorophenylacetamide	
2- <i>p</i> -chlorophenyl-2-(4-hydroxy-1- <i>o</i> -methoxyphenethyl-4-piperidyl)- <i>N</i> -phenylacetamide	
2-(4-hydroxy-1-phenethyl-4-piperidyl)- <i>N</i> -phenyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-3-cyclohexyl- <i>N</i> , <i>N</i> -dimethylpropionamide	M.P. (hydrogen fumarate) 134—136° (from acetone)

EXAMPLE 7.

2-(4-hydroxy-1-phenethyl-4-piperidyl)-propionic acid ethyl ester [process variant b)]

- 5 A solution of 6.4 g of propionic acid ethyl ester in 25 cc of anhydrous tetrahydrofuran is added dropwise at -75° to a solution of *N*,*N*-diisopropyl-lithium amide (produced from 8.9 cc of diisopropylamine in 60 cc of anhydrous tetrahydrofuran and 25 cc of a 20% *n*-butyl-lithium solution in hexane at a temperature of -75°). After stirring at the same temperature for one hour, a solution of 12.5 g of 1-phenethyl-4-piperidone in 50 cc of tetrahydrofuran is added within 20 minutes and the mixture is allowed to react at about -70° for a further 2 hours. The reaction temperature is then allowed to rise to about -10° and the reaction mixture is decomposed with 100 cc of water. After extracting repeatedly with ether, the crude product is isolated by concentrating the extracts which have been dried over magnesium sulphate. The resulting red-coloured oil is dissolved in acetone, the calculated amount of maleic acid is added and the resulting crude crystalline product is recrystallized repeatedly from acetone. The hydrogen maleate form of the title compound, having a M.P. of 138—139°, is obtained.
- 10 The compounds described in Example 3 may also be obtained in a manner analogous to that described in Example 7, by reacting the corresponding 1-phenethyl-4-piperidone derivatives with the corresponding carboxylic acid esters. Also are obtained 2-(1-*o*-chlorophenethyl)-4-hydroxy-4-piperidyl-3-butenic acid ethyl ester, M.P. (hydrogen fumarate) 181—183° [from ethanol (ether)] and 2-(1-*o*-chloro-phenethyl-4-hydroxy-4-piperidyl)-4-methyl-3-pentenoic acid ethyl ester.
- 15
- 20

EXAMPLE 8.

2-(4-hydroxy-1-phenethyl-4-piperidyl)-N,N-dimethyl propionamide

A solution of 5.05 g of N,N-dimethylpropionic acid amide in 25 cc of anhydrous tetrahydrofuran is added dropwise, while stirring, to a solution of N,N-diisopropyl-lithium amide (produced from 8.9 cc of diisopropylamine in 75 cc of anhydrous tetrahydrofuran and 25 cc of a 20% n-butyl-lithium solution in hexane at a temperature of -75°). The reaction mixture is stirred at -75° for one hour, and a solution of 10.2 g of 1-phenethyl-4-piperidone in 30 cc of anhydrous tetrahydrofuran is then added dropwise at the same temperature. After a reaction time of one hour at -75° , the temperature is allowed to rise to about -10° and the reaction mixture is then decomposed with 50 cc of a 20% potassium carbonate solution. Extraction is repeatedly effected with ether, the dried extracts are concentrated by evaporation and the semi-crystalline crude base is dissolved in ethanol. After the addition of an equivalent amount of fumaric acid, ether is added until the solution becomes turbid and the resulting crude crystalline product is purified by recrystallizing again from ethanol. The hydrogen fumarate form of the title compound, having a M.P. of $188-189^{\circ}$, is obtained.

The following compounds may also be obtained in a manner analogous to that described in Example 8, by reacting the corresponding 1-phenethyl-4-piperidone derivatives with the corresponding carboxylic acid amides:

Compound	Observations, physical constants
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N-p-chlorophenyl-N-methylbutenoic acid amide	
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N-m-tolyl-N-methylpropionamide	
2-(1-m-chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-isopropyl propionamide	
1-[2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-propionyl]-thiomorpholine	
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dibutyl-2-cyclohexyl-acetamide	M.P. of the hydrogen fumarate form: $159.5-160.5^{\circ}$ (from ethanol)
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dibutyl-propionamide	M.P. of the hydrogen maleate form: $140-141.5^{\circ}$ (from acetone/ether)
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methylpropionic acid amide	M.P. of the hydrogen maleate form: $121-123^{\circ}$ (from acetone)
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dimethyl propionamide	M.P. of the hydrogen fumarate form: $156-158^{\circ}$ (from ethanol/ether)
2-(4-hydroxy-1-phenethyl-4-piperidyl)-N,N-dimethyl-2-cyclohexyl-acetamide	M.P. of the hydrobromide form: $218-219^{\circ}$ (from ethanol/ether)
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N,N-dimethyl-2-cyclohexyl-acetamide	M.P. of the hydrobromide form: $203.5-205^{\circ}$ (from ethanol)
2-(1-o-chlorophenethyl-4-hydroxy-4-piperidyl)-N-methyl-N-phenyl propionamide	M.P. of the hydrogen maleate form: $170.5-171.5^{\circ}$ (from ethanol)
2-(1-o-fluorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methyl propionamide	

20

1,475,151

20

Compound	Observations, physical constants
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionyl]-4-methylpiperazine	M.P. of the dihydrochloride form: 283—284° (from ethanol)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-isobutyric acid N,N-dimethylamide	M.P. (hydrogen fumarate) 196—197°
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2-methyl-propionyl]piperidine	M.P. 132—133° (from acetone)
1-[2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-propionyl]-morpholine	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-methyl-N-phenyl-2- <i>m</i> -tolyl-acetamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N- <i>p</i> -fluorophenyl-N-methyl propionamide	
N-benzyl-2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-3-cyclohexyl-N-methyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-2- <i>p</i> -chlorophenyl-N,N-dimethylacetamide	
1-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methyl-1-cyclohexanecarboxylic acid amide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-2- <i>p</i> -methoxyphenyl-N-methylacetamide	M.P. (hydrochloride) 238—239° (from ethanol/ether)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-methyl isobutyric acid amide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-N-isopropyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-isopropyl-N-methyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-2- <i>p</i> -fluorophenyl-N-methylacetamide	
N-cyclohexyl-2-(1- <i>m</i> -methylphenethyl-4-hydroxy-4-piperidyl)-N-methyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-cyclohexyl-2-phenyl-N-methylacetamide	
2-(4-hydroxy-1- <i>o</i> -methoxyphenethyl-4-piperidyl)-N-cyclohexyl-N-methyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-3-cyclohexyl-N,N-dimethylpropionic acid amide	M.P. (hydrogen fumarate) 134—136° (from acetone)
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-butylpropionamide	M.P. (hydrogen maleate) 132—133° (from acetone/ether)

EXAMPLE 9.

2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)-N-phenylpropionamide
 48 cc of *n*-butyl-lithium in hexane are added dropwise at 0°, in an atmosphere of nitrogen with stirring, to a solution of 9 g of N-phenylpropionamide in 90 cc of anhydrous tetrahydrofuran. The mixture is stirred at 45–48° for 2½ hours and a solution of 10.5 g of N-*o*-chlorophenethyl-4-piperidine in 25 cc of anhydrous tetrahydrofuran is added dropwise within 50 minutes. The heating (oil bath) is removed and the reaction mixture is stirred for a further hour while cooling slowly. 10 cc of a 20% potassium carbonate solution are subsequently added to the reaction solution while stirring and cooling with ice, dilution is effected with ether and the organic phase is decanted, dried over magnesium sulphate and concentrated by evaporation at reduced pressure. The resulting crude compound is filtered over silica gel (eluant: chloroform containing 3% of methanol) and an equivalent amount of fumaric acid is added to the resulting title compound in ethanol whereby this crystallizes as hydrogen fumarate. The hydrogen fumarate form of the title compound has a M.P. of 159–161°.

The following compounds may be obtained in a manner analogous to that described in Example 9, by reacting the corresponding 1-phenethyl-4-piperidone derivatives with the corresponding N-phenylcarboxylic acid amides:

Compound	Observations, physical constants
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N-phenyl isobutyric acid amide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N- <i>p</i> -chlorophenyl propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N- <i>p</i> -tolyl-propionamide	
2-(1- <i>o</i> -chlorophenethyl-4-hydroxy-4-piperidyl)-N- <i>m</i> -methoxyphenyl propionamide	
2-(1- <i>o</i> -fluorophenethyl-4-hydroxy-4-piperidyl)-2-phenyl-N-phenyl-acetamide	
2-cyclohexyl-2-(4-hydroxy-1- <i>m</i> -methylphenethyl-4-piperidyl)-N- <i>p</i> -fluorophenyl acetamide	
2- <i>p</i> -chlorophenyl-2-(4-hydroxy-1- <i>o</i> -methoxyphenethyl-4-piperidyl)-N-phenylacetamide	
2-(4-hydroxy-1-phenethyl-4-piperidyl)-N-phenyl propionamide	

EXAMPLE 10.

2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)propionamide
[process variant d)]

20 cc of a 40% hydrogen peroxide solution are added dropwise within 15 minutes, while stirring and cooling with ice, to a solution of 17.5 g of 2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)propionitrile in 100 cc of 95% ethanol and 20 cc of 3 N caustic soda solution. The mixture is then allowed to stand at room temperature for 18 hours and the ethanol is subsequently evaporated at reduced pressure. 100 cc of a 4.4 N sodium bisulphite solution are slowly added to the aqueous phase while cooling strongly with ice and stirring, the reaction mixture is allowed to stand at 20° for 20 hours and is made alkaline with an excess of 5 N caustic soda solution. Extraction is effected several times with chloroform; the organic phase is washed with water, dried over magnesium sulphate and concentrated by evaporation at reduced pressure. The resulting crude title compound crystallizes from acetone and has a M.P. of 141–142°. The corresponding hydrogen maleate form of the title compound has a M.P. of 219–221°.

The starting material may be obtained as follows:

- a) 48 cc of n-butyl-lithium in hexane are added dropwise at 0°, in an atmosphere of nitrogen and with stirring, to a solution of 17 cc of diisopropylamine in 250 cc of anhydrous tetrahydrofuran. The mixture is stirred at 0° for a further 15 minutes, is cooled to -70°, and 4.2 cc of propionitrile in 10 cc of anhydrous tetrahydrofuran are added dropwise while stirring. The reaction mixture is stirred at -70° for one hour and subsequently a solution of 14.2 g of *o*-chlorophenethylpiperidin-4-one in 25 cc of anhydrous tetrahydrofuran is added dropwise and the mixture is stirred at -70° for a further hour. The temperature is raised to 0°, 5 cc of a 20% potassium carbonate solution are added to the reaction mixture and the organic phase is decanted. The residue is washed twice with ether, the combined solvent phases are dried over magnesium sulphate and concentrated by evaporation at reduced pressure. Fumaric acid is added to the resulting 2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)propionitrile in acetone and the fumarate is crystallized with the addition of ether. The fumarate has a M.P. of 187—189°.

The following (4-hydroxy-4-piperidyl)-carboxylic acid amide derivatives may also be obtained in a manner analogous to that described in Example 10, by hydrolysis of the corresponding nitriles produced in accordance with Example 10 a):

- 2-(4-hydroxy-1-phenethyl-4-piperidyl)isobutyric acid amide,
2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)butenoic acid amide,
2-[1-(4-*p*-fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]propionic acid amide,
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]propionic acid amide,
2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-2-phenylacetamide,
2-cyclohexyl-2-[1-(4-*p*-fluorophenyl-4-oxobutyl)-4-hydroxy-4-piperidyl]acetamide.

EXAMPLE 11.

2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)-N-butylpropionamide [process variant e)]

A solution of 5 g of 2-(1-*o*-chlorophenethyl-4-hydroxy-4-piperidyl)propionic acid phenyl ester and 50 cc of n-butylamine is boiled at reflux for 18 hours in an atmosphere of nitrogen. The excess n-butylamine is then removed by evaporation at reduced pressure, the residue is taken up in chloroform and the organic phase is washed twice with water and dried over magnesium sulphate. The chloroform is evaporated at reduced pressure. The residue is treated with maleic acid in acetone and the title compound is crystallized from acetone/ether (M.P. of hydrogen maleate 132—133°C).

The amide compounds described in Examples 4—7 may also be obtained in a manner analogous to that described in Example 11, by reacting the corresponding (4-hydroxy-4-piperidyl)carboxylic acid phenyl ester derivatives with the corresponding amines.

EXAMPLE 12. Galenic preparations

a) Capsules

Composition:

2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-propionic acid ethyl ester hydrochloride	20 mg
mannitol	200 mg
microcrystalline cellulose	75 mg
talc	15 mg
yields one capsule of	310 mg

b) Tablets

Composition:

	2-[4-hydroxy-1-(4-oxo-4-phenylbutyl)-4-piperidyl]-propionic acid ethyl ester hydrochloride	10 mg/dose
5	lactose	255 mg/dose
	maize starch	33 mg/dose
	polyvinyl pyrrolidone (Kollidon 30)	20 mg/dose
	magnesium stearate	2 mg/dose

10 The active agent is mixed with the lactose and the maize starch and is worked up with the remaining components in accordance with known tableting techniques into tablets of 320 mg.

The compounds of formula I exhibit pharmacological activity. In particular they exhibit analgesic activity as indicated in standard tests in mice, for example, in the tail flick test and the phenylbenzoquinone syndrome test.

15 The compounds are therefore indicated for use as analgesic agents. For this use an indicated daily dose is from 50 to 500 mg, conveniently administered in divided doses 2 to 4 times a day in unit dosage form containing from 12 to 250 mg, or in sustained release form.

20 The compounds of formula I may be administered in pharmaceutically acceptable acid addition salt form. Such acid addition salt forms exhibit the same order of activity as the free base forms and are readily prepared in conventional manner. The present invention also provides a pharmaceutical composition comprising a compound of formula I, in free base form or in pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent. Preferred compositions are those having R₂ ethoxy, R₃ phenyl, substituted phenyl or alkyl and R₄ hydrogen.

30 For example, the pharmaceutical compositions may be used in the form of tablets, dragees, powders, granulates, capsules, sirups and elixirs for oral administration, suppositories for rectal administration, and in the form of solutions, suspensions, dispersions and emulsions for parenteral administration. The pharmaceutical compositions may contain the above active agents alone or in admixture with the usual adjuvants and carrier materials, e.g. solvents such as ethanol, glycerin, water, solid carrier materials such as talc, lactose, starch, polyvinylpyrrolidone, magnesium stearate, natural or hardened oils and waxes. The compositions may also contain suitable preserving, stabilizing or wetting agents, solubilizers, taste improving agents, colouring, flavouring and lubricating agents.


40 The invention also provides a process for the production of a pharmaceutical composition including the step of working up a compound of formula I in a state of purity suitable for pharmaceutical acceptability with a pharmaceutical carrier or diluent.

In one group of compounds R₁ is phenethyl or substituted phenethyl.

In another group of compounds R₁ is 3-benzoylpropyl or substituted 3-benzoylpropyl.

45 Further groups are R₂ is alkyl, cycloalkyl or cycloalkylalkyl and R₃ is i) hydrogen or alkyl or ii) hydrogen or iii) R₃ and R₄ form a cycloalkyl ring together with the carbon atom to which they are bound.

Further groups are R₄ is i) alkoxy or ii)



50 wherein R₆ and R₇ are as defined above provided that R₆ and R₇ are other than hydrogen.

22
24


1,475,151

24

In another group of compounds R_2 is other than alkoxy when R_3 is alkyl or phenyl or substituted phenyl and R_4 is hydrogen.

WHAT WE CLAIM IS:—


1. A process for the production of a compound of formula I



wherein R_1 is phenethyl, phenethyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms; 3-benzoylpropyl or 3-benzoylpropyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,

R_2 is an OR_3 group,

wherein R_3 is alkyl of 1 to 4 carbon atoms, alkenyl of 3 to 5 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or an



wherein independently each of R_6 and R_7 is hydrogen, alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms), cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, phenylalkyl (of 1 to 4 carbon atoms) or phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or

wherein R_6 and R_7 together with the nitrogen atom to which they are bound, form a saturated heterocycle of 5 to 6 ring members, which may optionally contain as second hetero atom oxygen, sulphur or nitrogen substituted by alkyl of 1 to 4 carbon atoms,


R_3 is alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms), cycloalkyl of 4 to 6 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or when R_1 is phenethyl or phenethyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, alternatively alkenyl of 2 to 4 carbon atoms, and

R_4 is hydrogen or alkyl of 1 to 4 carbon atoms, or

R_3 and R_4 together with the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms.

which comprises

a) reacting a compound of formula II,




wherein R_2 and R_4 are as defined above, and

In another group of compounds R_2 is other than alkoxy when R_1 is alkyl or phenyl or substituted phenyl and R_4 is hydrogen.

WHAT WE CLAIM IS:—


1. A process for the production of a compound of formula I



wherein R_1 is phenethyl, phenethyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, 3-benzoylpropyl or 3-benzoylpropyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,

R_2 is an OR, group,

wherein R_3 is alkyl of 1 to 4 carbon atoms, alkenyl of 3 to 5 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or an



wherein independently each of R_6 and R_7 is hydrogen, alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms), cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, phenylalkyl (of 1 to 4 carbon atoms) or phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or

wherein R_6 and R_7 together with the nitrogen atom to which they are bound, form a saturated heterocycle of 5 to 6 ring members, which may optionally contain as second hetero atom oxygen, sulphur or nitrogen substituted by alkyl of 1 to 4 carbon atoms,


R_3 is alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms), cycloalkyl of 4 to 6 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or when R_1 is phenethyl or phenethyl monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, alternatively alkenyl of 2 to 4 carbon atoms, and

R_4 is hydrogen or alkyl of 1 to 4 carbon atoms, or

R_3 and R_4 together with the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms.

which comprises

a) reacting a compound of formula II,



wherein R_3 and R_4 are as defined above, and




33

25

1,475,151


25

5 R_3^I is alkyl of 1 to 4 carbon atoms, cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms) cycloalkyl of 4 to 6 carbon atoms, phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or together with R_4 and the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms, with a compound of formula III,



wherein R_1 is as defined above, and
X is the acid radical of a reactive ester, to produce a compound of formula Ia,


10



Ia

10

wherein R_1 , R_2 , R_3^I and R_4 are as defined above, or
b) producing a compound of formula Ia,



Ia


wherein R_3 and R_4 are as defined above,

15

R_3^I is an OR_5 group,

15

wherein R_5 is as defined above, or an



20

wherein R_5^I is alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms) cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, phenylalkyl (of 1 to 4 carbon atoms) or phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,

20

25

R_5^I is hydrogen when R_3^I and/or R_4 are phenyl or substituted phenyl, or

25

30

R_5^I is alkyl of 1 to 4 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms) cycloalkyl of 4 to 6 carbon atoms, phenyl, phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms phenylalkyl (of 1 to 4 carbon atoms) or phenylalkyl (of 1 to 4 carbon atoms) monosubstituted in the phenyl ring by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, when R_3^I is alkyl of 1 to 4 carbon atoms, cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms) or cycloalkyl of 4 to 6 carbon atoms, or R_4 is hydrogen and R_3^I is phenyl or phenyl monosubstituted

30

34




26

1,475,151

26


- 5 by fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms, or
- 5 R_1^I and R_2^I together with the nitrogen atom to which they are bound form a saturated heterocycle of 5 to 6 ring members, which may optionally contain as second hetero atom oxygen, sulphur, or nitrogen substituted by alkyl of 1 to 4 carbon atoms, and
- 5 R_3 is fluorine, chlorine, bromine, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms by reacting a compound of formula IV,



IV

- 10 wherein R_3 is as defined above, with a compound of formula V,


10



V

wherein R_3 , R_4 and R_2^I are as defined above, or


- c) producing a compound of formula Ib,



Ib

- 15 wherein R_2 , R_3^I , R_4 and R_3 are as defined above, by removing the protective group from a compound of formula VI,

15




VI

wherein R_2 , R_3^I , R_4 and R_3 are as defined above, and A is a carbonyl group protected by ketal formation, or

- 20 d) producing a compound of formula Ic,

20



Ic

wherein R_1 , R_3 and R_4 are as defined above,




35

27

1,475,151


27

by hydrolyzing the CN group to an $\text{NH}_2\text{—CO}$ group in a compound of formula VII,




VII

wherein R_1 , R_3 and R_4 are as defined above, or
e) producing a compound of formula Id,




Id

wherein R_1 , R_3 , R_4 and R_7 are as defined above,
by reacting a compound of formula Ie,



Ie

wherein R_1 , R_3 and R_4 are as defined above, and
 R_5 is phenyl or phenyl monosubstituted by fluorine, chlorine, bromine, alkyl of
1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms,
with a compound of formula VIII,



wherein R_6 and R_7 are as defined above.

2. A process for the production of a compound of formula Ic defined in Claim 1, which comprises reducing an N-oxide of a compound of formula Ic.

3. A process for the production of a compound of formula I, as stated in Claim 1, substantially as hereinbefore described with reference to any one of the Examples 1 to 11.

4. A process for the production of a pharmaceutical composition which comprises working up a compound of formula I in a state of purity sufficient for pharmaceutical acceptability together with a pharmaceutical carrier or diluent.

5. A process according to Claim 4, substantially as hereinbefore described with reference to Example 12.

6. A compound of formula I, whenever produced by a process according to Claim 1, 2 or 3.

7. A compound of formula I, as defined in Claim 1.

8. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - propionic acid ethyl ester.

9. 2 - [1 - (4 - p - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - propionic acid ethyl ester.

10. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - butyric acid ethyl ester.

11. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2 - cyclohexyl - acetic acid ethyl ester.



12. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - isobutyric acid ethyl ester.
13. 1 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 1 - cyclopentane - carboxylic acid ethyl ester.
14. 2 - cyclopentyl - 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl]acetic acid ethyl ester.
15. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 3 - cyclopentyl - propionic acid ethyl ester.
16. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 3 - cyclohexyl propionic acid ethyl ester.
17. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - propionic acid tert.butyl ester.
18. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - isobutyric acid ethyl ester.
19. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - isobutyric acid methyl ester.
20. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - propionic acid *o*-tolyl ester.
21. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - *m* - tolylbutyl) - 4 - piperidyl] - isobutyric acid ethyl ester.
22. 2 - [4 - hydroxy - 1 - (4 - *p* - methoxyphenyl - 4 - oxobutyl) - 4 - piperidyl] - propionic acid ethyl ester.
23. 2 - [1 - (4 - *p* - chlorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - 2 - phenylacetic acid ethyl ester.
24. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - isobutyric acid allyl ester.
25. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - propionic acid phenyl ester.
26. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - propionic acid *m*-methoxyphenyl ester.
27. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - butyric acid *p*-chlorophenyl ester.
28. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2 - *p*-chlorophenylacetic acid ethyl ester.
29. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2 - phenylacetic acid ethyl ester.
30. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - 2 - *m* - tolyl - acetic acid ethyl ester.
31. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - 2 - *p*-methoxyphenylacetic acid ethyl ester.
32. 2 - (4 - hydroxy - 4 - piperidyl - 1 - phenethyl - 4 - piperidyl)propionic acid ethyl ester.
33. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid isopropyl ester.
34. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid tert.butyl ester.
35. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - phenylacetic acid ethyl ester.
36. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - *p* - chlorophenylacetic acid ethyl ester.
37. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid phenyl ester.
38. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid methyl ester.
39. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - isobutyric acid ethyl ester.
40. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 3 - butenoic acid ethyl ester.
41. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid allyl ester.
42. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 4 - methyl-3 - pentenoic acid ethyl ester.
43. 2 - (4 - hydroxy - 1 - *p* - methoxyphenethyl - 4 - piperidyl) - propionic acid ethyl ester.



* C L M S *

3-7-74

44. 2 - (4 - hydroxy - 1 - *m*-methylphenethyl - 4 - piperidyl) - propionic acid ethyl ester.
45. 2 - (1 - *p* - fluorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid ethyl ester. 5
46. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - *p* - fluoro-phenylacetic acid ethyl ester. 5
47. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - *m*-methoxyphenylacetic acid ethyl ester.
48. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - *p* - tolyl-acetic acid ethyl ester. 10
49. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid *p*-chlorophenyl ester.
50. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid *o*-tolyl ester.
51. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionic acid *p*-fluorophenyl ester. 15
52. 1 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 1 - cyclo-hexane - carboxylic acid ethyl ester.
53. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl)isobutyric acid allyl ester. 20
54. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N,N-dimethyl propionamide.
55. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl]-N - phenyl - propionamide. 25
56. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N-cyclohexyl - N - methyl propionamide.
57. 2 - [1 - (4 - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl]-N,N - dimethyl propionamide.
58. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N-methyl - N- phenyl propionamide. 30
59. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl]-N - methyl - N - phenyl propionamide.
60. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl]-N,N - dimethylisobutyric acid amide. 35
61. 1 - [2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl]-2 - methylpropionyl]pyrrolidine. 35
62. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N-isopropyl - N - methyl isobutyric acid amide.
63. N - cyclohexyl - 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N - isopropyl - propionamide. 40
64. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - *o* - tolylbutyl) - 4 - piperidyl] - N - *p*-chlorophenyl - N - methyl propionamide.
65. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N - cyclo-hexyl - N - methyl - 2 - phenylacetamide. 45
66. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - N - *p* - fluorophenyl - N - methyl propionamide.
67. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl]-N - *m* - methoxyphenyl propionamide.
68. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl]-2 - *p* - chlorophenyl - N - *o* - tolyl - acetamide. 50
69. 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - propionamide.
70. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - propionamide.
71. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2-phenylacetamide. 55
72. 2 - cyclohexyl - 2 - [1 - (4 - *p* - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy-4 - piperidyl]acetamide.
73. N - cyclohexyl - 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - N - isopropyl - isobutyric acid amide.
74. N - cyclohexyl - 2 - [4 - hydroxy - 1 - (4 - *p* - chlorophenyl - 4 - oxobutyl)-4 - piperidyl] - N - methyl propionamide. 60
75. 1 - [2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl]-2 - methylpropionyl] - 4 - methylpiperazine.
76. 1 - [2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2 - methylpropionyl]morpholine. 65

38



* C L M S *

1,475,151

30

30

	77. 1 - [2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2 - methylpropionyl]thiomorpholine.	
	78. 2 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 2 - cyclohexyl - N,N - dimethylacetamide.	
5	79. 2 - [1 - (4 - p - methoxyphenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - N - benzyl - N - methyl propionamide.	5
	80. 1 - [4 - hydroxy - 1 - (4 - oxo - 4 - phenylbutyl) - 4 - piperidyl] - 1 - cyclohexane - carboxylic acid N,N - dimethylamide.	
10	81. 2 - [1 - (4 - p - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - N - isopropyl - N - methyl - 2 - p methoxyphenylacetamide.	10
	82. 2 - [1 - (4 - p - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - 2 - p - fluorophenyl - N,N - dimethyl acetamide.	
	83. 2 - [1 - (4 - p - fluorophenyl - 4 - oxobutyl) - 4 - hydroxy - 4 - piperidyl] - N,N - dimethyl - 2 - m - tolyl - acetamide.	
15	84. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - butylpropionamide.	15
	85. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - m - tolyl - N - methyl propionamide.	
20	86. 2 - (1 - m - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - N - isopropyl propionamide.	20
	87. 1 - [2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionyl]thiomorpholine.	
	88. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N,N - dibutyl - 2 - cyclohexyl - acetamide.	
25	89. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N,N - dibutylpropionamide.	25
	90. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - N - methylpropionic acid amide.	
30	91. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N,N - dimethyl propionamide.	30
	92. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N,N - dimethyl - 2 - cyclohexyl - acetamide.	
	93. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - methyl - N - phenyl propionamide.	
35	94. 2 - (1 - o - fluorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - N - methyl propionamide.	35
	95. 1 - [2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionyl] - 4 - methylpiperazine.	
40	96. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - isobutyric acid N,N - dimethylamide.	40
	97. 1 - [2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - methylpropionyl]piperidine.	
	98. 1 - [2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionyl]morpholine.	
45	99. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - methyl - N - phenyl - 2 - m - tolyl - acetamide.	45
	100. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - p - fluorophenyl - N - methylpropionamide.	
50	101. N - benzyl - 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 3 - cyclohexyl - N - methylpropionamide.	50
	102. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 2 - p - chlorophenyl - N,N - dimethylacetamide.	
	103. 1 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - N - methyl - 1 - cyclohexane - carboxylic acid amide.	
55	104. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - 2 - p - methoxyphenyl - N - methylacetamide.	55
	105. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - N - methyl isobutyric acid amide.	
60	106. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - N - isopropyl propionamide.	60
	107. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - isopropyl - N - methyl propionamide.	
	108. 2 - (1 - o - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - 2 - p - fluorophenyl - N - methylacetamide.	




39

31

1,475,151


31

109. N - cyclohexyl - 2 - (1 - *m* - methylphenethyl - 4 - hydroxy - 4 - piperidyl) - N - methyl propionamide.
110. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - cyclohexyl - 2 - phenyl - N - methylacetamide.
111. 2 - (4 - hydroxy - 1 - *o* - methoxyphenethyl - 4 - piperidyl) - N - cyclohexyl - N - methyl propionamide.
112. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - phenyl isobutyric acid amide.
113. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - *p* - chlorophenyl propionamide.
114. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - *p* - tolylpropionamide.
115. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - *m* - methoxyphenyl propionamide.
116. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - N - phenyl propionamide.
117. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - propionamide.
118. 2 - *p* - chlorophenyl - 2 - (4 - hydroxy - 1 - *o* - methoxyphenethyl - 4 - piperidyl) - N - phenylacetamide.
119. 2 - (4 - hydroxy - 1 - phenethyl - 4 - piperidyl) - N - phenyl propionamide.
120. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl) - 3 - cyclohexyl - N,N - dimethylpropionamide.
121. A compound of Claim 7, wherein R₁ is phenethyl or substituted phenethyl.
122. A compound of Claim 121, wherein R₂ is alkyl of 1 to 4 carbon atoms, cycloalkyl of 4 to 6 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms).
123. A compound of Claim 122, wherein R₄ is hydrogen or alkyl of 1 to 4 carbon atoms.
124. A compound of Claim 122, wherein R₄ is hydrogen.
125. A compound of Claim 122, wherein R₃ and R₄ together with the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms.
126. A compound of any one of Claims 121 to 125, wherein R₂ is alkoxy of 1 to 4 carbon atoms.
127. A compound of any one of Claims 121 to 125, wherein R₂ is



wherein R₆ and R₇ are both other than hydrogen.

128. A compound of Claim 7, wherein R₂ is 3-benzoylpropyl or substituted 3-benzoylpropyl.
129. A compound of Claim 128, wherein R₃ is alkyl of 1 to 4 carbon atoms, cycloalkyl of 4 to 6 carbon atoms or cycloalkyl (4 to 6 carbon atoms) alkyl (1 to 4 carbon atoms).
130. A compound of Claim 129, wherein R₄ is hydrogen or alkyl of 1 to 4 carbon atoms.
131. A compound of Claim 129, wherein R₄ is hydrogen.
132. A compound of Claim 129, wherein R₃ and R₄ together with the carbon atom to which they are bound form a cycloalkyl ring of 4 to 6 carbon atoms.
133. A compound of any one of Claims 128 to 140, wherein R₂ is alkoxy of 1 to 4 carbon atoms.
134. A compound of any one of Claims 128 to 140, wherein R₂ is



wherein R₆ and R₇ are both other than hydrogen.



32

1,475,151

32

135. A compound of Claim 7, wherein R_2 is other than ethoxy when R_3 is alkyl of 1 to 4 carbon atoms, phenyl or substituted phenyl and R_4 is hydrogen.
136. 2 - cyclohexyl - 2 - (4 - hydroxy - 1 - *m* - methylphenethyl - 4 - piperidyl) - N fluorophenyl acetamide.
137. 2 - (4 - hydroxy - 1 - phenethyl - 4 - piperidyl)isobutyric acid amide.
138. 2 - (1 - *o* - chlorophenethyl - 4 - hydroxy - 4 - piperidyl)butenoic acid amide.
139. A compound according to any one of Claims 6 to 138 in free base form.
140. A compound according to any one of Claims 6 to 138 in acid addition salt form.
141. A pharmaceutical composition comprising a compound of any one of Claims 6 to 138 in free base form or in pharmaceutically acceptable acid addition salt form in association with a pharmaceutical carrier or diluent.
142. A pharmaceutical composition comprising a compound of formula I stated in Claim 1, wherein R_2 is ethoxy, R_3 is phenyl, substituted phenyl or alkyl of 1 to 4 carbon atoms and R_4 is hydrogen in association with a pharmaceutical carrier or diluent.
143. A pharmaceutical composition according to Claim 141 or 142 substantially as hereinbefore described.
144. A pharmaceutical composition whenever produced by the process of Claim 4 or 5.

B. A. YORKE & CO.,
Chartered Patent Agents,
98, The Centre,
Feltham,
Middlesex TW13 4EP.
Agents of the Applicants.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1977.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.